Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2013-05-03

Clinical Trial Update: Ranibizumab as a Rescue Therapy for Diabetic Macular Edema [Phase 2]

View source ↗

Summary

The Phase 2 trial of ranibizumab as rescue therapy for diabetic macular edema has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lucentis (ranibizumab)

Snippet

Sponsor: New England Retina Associates | Conditions: Diabetic Macular Edema | Phase 2 | Status: WITHDRAWN